Persistent minority K103N mutations among women exposed to single-dose nevirapine and virologic response to nonnucleoside reverse-transcriptase inhibitor-based therapy

Clinical Infectious Diseases

Volumn 48, Issue 4, 2009, Pages 462-472

  Coovadia, Ashraf ^a   Hunt, Gillian ^e   Abrams, Elaine J ^f   Sherman, Gayle ^c,d   Meyers, Tammy ^b   Barry, Gill ^a   Malan, Eloise ^a   Marais, Belinda ^a   Stehlau, Renate ^a   Ledwaba, Johanna ^e   Hammer, Scott M ^f   Morris, Lynn ^e   Kuhn, Louise ^g,h  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^b UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^c UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^d NATIONAL HEALTH LABORATORY SERVICE   (South Africa)

^e NATIONAL INSTITUTE FOR COMMUNICABLE DISEASES   (South Africa)

^f Och Spine at New York Presbyterian Hospitals   (United States)

^g NONE   (United States)

^h Taub Institute for Research on Alzheimer's Disease and the Aging Brain and the Gertrude H Sergievsky Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIDANOSINE; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; VIRUS DNA; VIRUS RNA; ZIDOVUDINE;

ADULT; ALLELE; ARTICLE; CONTROLLED STUDY; DRUG EXPOSURE; DRUG SUBSTITUTION; FEMALE; GENE MUTATION; GENE SEQUENCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; NUCLEOTIDE SEQUENCE; PATIENT COMPLIANCE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REBOUND; SINGLE DRUG DOSE; SOUTH AFRICA; TREATMENT OUTCOME; VIRUS INHIBITION; VIRUS LOAD;

ADULT; AMINO ACID SUBSTITUTION; ANTI-HIV AGENTS; DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; LONGITUDINAL STUDIES; MOLECULAR SEQUENCE DATA; MUTATION, MISSENSE; NEVIRAPINE; SEQUENCE ANALYSIS, DNA; SOUTH AFRICA; TREATMENT OUTCOME; VIRAL LOAD;

EID: 58749088735     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/596486     Document Type: Article

References (29)

1. Jackson JB, Musoke P, Fleming T, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 012 randomised trial. Lancet 2003; 362:859-68.
2. Dao H, Mofenson LM, Ekpini R, et al. International recommendations on antiretroviral drugs for treatment of HIV-infected women and prevention of mother-to-child HIV transmission in resource-limited settings: 2006 update. Am J Obstet Gynecol 2007; 197:S42-55.
3. Sripipatana T, Spensley A, Miller A, et al. Site-specific interventions to improve prevention of mother-to-child transmission of human immunodeficiency virus programs in less developed settings. Am J Obstet Gynecol 2007; 197:S107-12.
4. Stringer JS, Sinkala M, Maclean CC, et al. Effectiveness of a city-wide program to prevent mother-to-child HIV transmission in Lusaka, Zambia. AIDS 2005; 19:1309-15.
5. Lallemant M, Jourdain G, Le Coeur S, et al. Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand. N Engl J Med 2004; 351:217-28.
6. Jackson JB, Becker-Pergola G, Guay LA, et al. Identification of the K103N resistance mutation in Ugandan women receiving nevirapine to prevent HIV-1 vertical transmission. AIDS 2000; 14:F111-5.
7. Eshleman SH, Becker-Pergola G, Deseyve M, et al. Impact of human immunodeficiency virus type 1 (HIV-1) subtype on women receiving single-dose nevirapine prophylaxis to prevent HIV-1 vertical transmission (HIV Network for Prevention Trials 012 study). J Infect Dis 2001; 184:914-7.
8. Eshleman SH, Hoover DR, Chen S, et al. Nevirapine (NVP) resistance in women with HIV-1 subtype C, compared with subtypes A and D, after the administration of single-dose NVP. J Infect Dis 2005; 192:30-6.
9. Eshleman SH, Hoover DR, Chen S, et al. Resistance after single-dose nevirapine prophylaxis emerges in a high proportion of Malawian newborns. AIDS 2005; 19:2167-9.
10. Hammer SM, Turmen T, Vareldzis B, Perriens J. Antiretroviral guidelines for resource-limited settings: the WHO's public health approach. Nature Med 2002; 8:649-50.
11. Jourdain G, Ngo-Giang-Huong N, Le Coeur S, et al. Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy. N Engl J Med 2004; 351:229-40.
12. Lockman S, Shapiro RL, Smeaton LM, et al. Response to antiretroviral therapy after a single, peripartum dose of nevirapine. N Engl J Med 2007; 356:135-47.
13. Chi BH, Sinkala M, Stringer EM, et al. Early clinical and immune response to NNRTI-based antiretroviral therapy among women with prior exposure to single-dose nevirapine. AIDS 2007; 21:957-64.
14. Loubser S, Balfe P, Sherman G, Hammer S, Kuhn L, Morris L. Decay of K103N mutants in cellular DNA and plasma RNA after single-dose nevirapine to reduce mother-to-child HIV transmission. AIDS 2006; 20:995-1002.
15. Eshleman SH, Mracna M, Guay LA, et al. Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012). AIDS 2001; 15:1951-7.
16. Palmer S, Boltz V, Martinson N, et al. Persistence of nevirapine-resistant HIV-1 in women after single-dose nevirapine therapy for prevention of maternal-to-fetal HIV-1 transmission. Proc Natl Acad Sci USA 2006; 103:7094-9.
17. Flys T, Nissley DV, Claasen CW, et al. Sensitive drug-resistance assays reveal long-term persistence of HIV-1 variants with the K103N nevirapine (NVP) resistance mutation in some women and infants after the administration of single-dose NVP. J Infect Dis 2005; 192:24-9.
18. Johnson JA, Li JF, Morris L, et al. Emergence of drug-resistant HIV-1 after intrapartum administration of single-dose nevirapine is substantially underestimated. J Infect Dis 2005; 192:16-23.
19. Flys TS, Donnell D, Mwatha A, et al. Persistence of K103N-containing HIV-1 variants after single-dose nevirapine for prevention of HIV-1 mother-to-child transmission. J Infect Dis 2007; 195:711-5.
20. Sherman GG, Jones SA, Coovadia AH, Urban MF, Bolton KD. PMTCT from research to reality - results from a routine service. S Afr Med J 2004; 94:289-92.
21. Felsenstein J. PHYLIP - phylogeny inference package (version 3.2). Cladistics 1989; 5:164-6.
22. Johnson JA, Li JF, Wei X, et al. Minority HIV-1 drug resistance mutations are present in antiretroviral treatment-naive populations and associate with reduced treatment efficacy. PLOS Med 2008; 5:e158.
23. Troyer RM, Lalonde MS, Fraundorf E, et al. A radiolabeled oligonucleotide ligation assay demonstrates the high frequency of nevirapine resistance mutations in HIV type 1 quasispecies of NVP-treated and untreated mother-infant pairs from Uganda. AIDS Res Hum Retroviruses 2008; 24:235-50.
24. Church JD, Hudelson SE, Guay LA, et al. HIV type 1 variants with nevirapine resistance mutations are rarely detected in antiretroviral drug-naive African women with subtypes A, C, and D. AIDS Res Hum Retroviruses 2007; 23:764-8.
25. Pillay V, Ledwaba J, Hunt G, et al. Antiretroviral drug resistance surveillance among drug-naive HIV-1 infected individuals in Gauteng Province, South Africa in 2002 and 2004. Antivir Ther 2008; 13(Supp 2):101-7.
26. Rowley CF, Boutwell C, Lockman S, Essex M. Improvement in allele-specific PCR assay with the use of polymorphism-specific primers for the analysis of minority variant drug resistance in HIV-1 subtype C. J Virol Methods 2008; 149:69-75.
27. Chi BH, Sinkala M, Mbewe F, et al. Single-dose tenofovir and emtricitabine for reduction of viral resistance to non-nucleoside reverse transcriptase inhibitor drugs in women given intrapartum nevirapine for perinatal HIV prevention: an open-label randomised trial. Lancet 2007; 370:1698-705.
28. Chaix ML, Ekouevi DK, Rouet F, et al. Low risk of nevirapine resistance mutations in the prevention of mother-to-child transmission of HIV-1: Agence Nationale de Recherches sur le SIDA Ditrame Plus, Abidjan, Cote d'Ivoire. J Infect Dis 2006; 193:482-7.
29. McIntyre J, Martinson N, Gray G, et al. Addition of short-course combivir (CBV) to single dose viramune (SDNVP) for prevention of mother-to-child transmission (PMTCT) of HIV-1 can significantly decrease the subsequent development of maternal and paediatric NNRTI-resistant virus [abstract TuFoO2O4]. In: Program and abstracts of the 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment (Rio de Janeiro). Stockholm: International AIDS Society, 2005.